Clinical Trial Update: 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 PET study evaluating dopamine synthesis capacity in the whole striatum after 2 weeks of ralmitaront versus placebo in people with schizophrenia. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Ralmitaront (ralmitaront)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED